← Back to Screener
Insulet Corporation (PODD)
Price$153.22
Value ScoreC
Growth ScoreA
Momentum ScoreD
Favorite Metrics
Price vs S&P 500 (26W)-61.10%
Price vs S&P 500 (4W)-0.60%
VGM Score50.47
Market Capitalization$10.61B
P/E Ratio (Annual)42.95x
All Metrics
P/CF (Annual)18.64x
Book Value / Share (Quarterly)$21.53
P/TBV (Annual)14.30x
Indicated Dividend (Annual)$0.00
Revenue Growth (3Y)27.54%
Cash Flow / Share (Quarterly)$4.97
Price vs S&P 500 (YTD)-54.25%
Gross Margin (TTM)71.01%
Net Profit Margin (TTM)10.44%
EPS (TTM)$4.29
10-Day Avg Trading Volume1.68M
EPS Excl Extra (TTM)$4.29
Revenue Growth (5Y)24.53%
EPS (Annual)$3.44
ROI (Annual)10.03%
Gross Margin (Annual)71.63%
Net Profit Margin (5Y Avg)8.67%
Cash / Share (Quarterly)$10.17
P/E Basic Excl Extra (TTM)35.04x
Revenue Growth QoQ (YoY)33.87%
EPS Growth (5Y)101.61%
P/E Normalized (Annual)42.95x
ROA (Last FY)7.75%
Revenue Growth TTM (YoY)31.93%
EBITD / Share (TTM)$7.34
ROE (5Y Avg)16.60%
Operating Margin (TTM)14.57%
Cash Flow / Share (Annual)$4.97
P/B Ratio7.00x
P/B Ratio (Quarterly)13.20x
Net Income / Employee (Annual)$45,800
EV / Revenue (TTM)4.00x
Net Interest Coverage (TTM)33.64x
ROA (TTM)7.49%
EPS Growth QoQ (YoY)171.66%
EV / EBITDA (TTM)24.63x
EPS Incl Extra (Annual)$3.44
Current Ratio (Annual)2.81x
Quick Ratio (Quarterly)1.81x
3-Month Avg Trading Volume1.26M
52-Week Price Return-51.69%
EV / Free Cash Flow (Annual)31.01x
P/E Incl Extra (TTM)35.04x
Revenue / Employee (TTM)$537,200
Tangible BV / Share (Quarterly)$19.86
P/S Ratio (Annual)3.92x
Asset Turnover (Annual)0.85x
52-Week High$354.88
Operating Margin (5Y Avg)10.26%
EPS Excl Extra (Annual)$3.44
CapEx CAGR (5Y)5.67%
Tangible BV CAGR (5Y)19.45%
26-Week Price Return-53.17%
Quick Ratio (Annual)1.81x
13-Week Price Return-36.41%
Total Debt / Equity (Annual)0.63x
Current Ratio (Quarterly)2.81x
Enterprise Value$10.85B
Revenue / Share Growth (5Y)22.38%
Asset Turnover (TTM)0.82x
Book Value / Share Growth (5Y)18.67%
Revenue / Employee (Annual)$501,500
Inventory Turnover (Annual)1.74x
Pretax Margin (Annual)12.54%
Cash / Share (Annual)$10.17
3-Month Return Std Dev50.18%
Gross Margin (5Y Avg)67.99%
Net Income / Employee (TTM)$56,100
EBITDA CAGR (5Y)32.73%
EBITDA Interim CAGR (5Y)38.50%
ROE (Last FY)16.31%
Net Interest Coverage (Annual)11.55x
EPS Basic Excl Extra (Annual)$3.44
P/FCF (TTM)27.37x
Receivables Turnover (TTM)6.14x
EV / Free Cash Flow (TTM)27.97x
Total Debt / Equity (Quarterly)0.63x
EPS Incl Extra (TTM)$4.29
Receivables Turnover (Annual)6.14x
ROI (TTM)9.20%
P/S Ratio (TTM)3.66x
Pretax Margin (5Y Avg)8.46%
Revenue / Share (Annual)$37.67
Tangible BV / Share (Annual)$19.86
Forward P/E20.43x
Price vs S&P 500 (52W)-76.06%
P/E Ratio (TTM)35.04x
EPS Growth TTM (YoY)-21.06%
Year-to-Date Return-46.09%
5-Day Price Return3.44%
EPS Normalized (Annual)$3.44
ROA (5Y Avg)6.06%
Net Profit Margin (Annual)9.12%
Month-to-Date Return5.71%
Cash Flow / Share (TTM)$2.67
EBITD / Share (Annual)$6.13
EPS Growth (3Y)273.82%
Operating Margin (Annual)12.92%
LT Debt / Equity (Annual)0.61x
P/CF (TTM)17.14x
ROI (5Y Avg)7.37%
P/E Excl Extra (TTM)35.04x
LT Debt / Equity (Quarterly)0.61x
EPS Basic Excl Extra (TTM)$4.29
P/TBV (Quarterly)14.30x
P/B Ratio (Annual)13.20x
Inventory Turnover (TTM)1.74x
Pretax Margin (TTM)13.94%
Book Value / Share (Annual)$21.53
Price vs S&P 500 (13W)-44.66%
Net Margin Growth (5Y)64.81%
Beta1.10x
P/FCF (Annual)30.34x
Revenue / Share (TTM)$41.32
ROE (TTM)17.37%
52-Week Low$140.63
vGradeC
gGradeA
mGradeD
vgmGradeC
Show chart for
Earnings Surprise History
Q1 261.42est. 1.22
Analyst Recommendations
Mar 2026
Apr 2026
May 2026
Jun 2026
4.26
4.26
4.18
4.24
Industry Peers — Surgical & Medical Instruments(138)
| Symbol | Value Score | Growth Score | Momentum Score | Price |
|---|---|---|---|---|
PODDInsulet Corporation | C | A | D | $153.22 |
| SYKStryker Corporation | C | C | C | $305.66 |
| MMM3M Company | C | F | C | $153.76 |
| BSXBoston Scientific Corp. | C | B | D | $48.55 |
| MDLNMedline Inc. Class A common stock | C | D | D | $33.61 |
| BDXBecton, Dickinson and Co. | B | C | C | $151.16 |
| RMDResMed Inc. | C | B | C | $196.04 |
| DXCMDexCom, Inc. | C | B | C | $72.86 |
| WSTWest Pharmaceutical Services, Inc. | D | C | B | $314.50 |
| SOLVSolventum Corporation | C | D | B | $81.01 |
| PENPenumbra, Inc. | F | C | B | $320.53 |
About
Insulet manufactures the Omnipod system, a smartphone-controlled, disposable insulin infusion device that simplifies continuous insulin therapy for diabetic patients. FDA-approved since 2005, the system has been adopted by approximately 500,000 patients worldwide, establishing Insulet as a leader in automated insulin delivery solutions.